Grifols (GRFS) Non Operating Interest Expenses (2010 - 2014)
Grifols' (GRFS) quarterly Non Operating Interest Expenses came in at $74.9 million in Q4 2014, up 14.34% YoY from $65.5 million in Q4 2013, and up 14.34% on a QoQ basis from $65.5 million in Q4 2013.
Grifols (GRFS) Non Operating Interest Expenses (2010 - 2014) Analysis & Trends
Grifols (GRFS) has 5 years of Non Operating Interest Expenses data on file, last reported at $74.9 million in Q4 2014.
- Quarterly Non Operating Interest Expenses rose 14.34% year-over-year to $74.9 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $626.3 million (up 42.47% YoY) and the FY2014 annual result came in at $79.6 million, up 24.63% from the prior year.
- Non Operating Interest Expenses improved to $74.9 million in Q4 2014, from $65.5 million in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $429.6 million in Q4 2011 to a low of -$111.8 million in Q3 2011.
- A 5-year average of $90.5 million and a median of $65.5 million in 2013 frame the typical range for Non Operating Interest Expenses.
- The widest YoY moves for Non Operating Interest Expenses: up 248.68% in 2011, down 2628.45% in 2011.
- Tracing GRFS's Non Operating Interest Expenses over 5 years: stood at $123.2 million in 2010, then soared by 248.68% to $429.6 million in 2011, then sank by 86.89% to $56.3 million in 2012, then increased by 16.27% to $65.5 million in 2013, then gained by 14.34% to $74.9 million in 2014.
- The last three Non Operating Interest Expenses figures came in at $74.9 million (Q4 2014), $65.5 million (Q4 2013), and $56.3 million (Q4 2012), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 74.88 Mn |
| Dec 31, 2013 | 65.49 Mn |
| Dec 31, 2012 | 56.32 Mn |
| Dec 31, 2011 | 429.63 Mn |
| Sep 30, 2011 | -111.83 Mn |
| Dec 31, 2010 | 123.21 Mn |
| Sep 30, 2010 | -4.10 Mn |